Day Two
Thursday November 21, 2024
07:30am Limited Places Available: Exclusive Breakfast Briefing, Considering Portfolio Strategy When Scaling Up Your Small/Mid-Sized Biotech
09:30am End of Breakfast Briefing
09:30am Conference Day Two Welcome Coffee
09:50am Chair’s Opening Remarks
Harnessing Technological Advancements in Strategic Decision-Making Processes
10:00am Fireside Chat: Strategic Integration: Balancing Human Expertise and Artificial Intelligence in Digital Transformation
Synopsis
- Overview of how AI is currently being utilized in biopharma
- Greatest opportunities for AI to enhance biopharma operations and decision-making processes
- Challenges and limitations associated with integrating AI into biopharma operations
- Ethical considerations surrounding AI adoption
- Exploring the optimal balance between human expertise and AI capabilities in decision-making processes Future trends in AI technology and their potential impact on biopharma
Leveraging Data Analytics for Data-Driven Decision Making in Portfolio Strategics
10:45am Architecture for Structured Decision-Making
Synopsis
- Understand how pharmaceutical and biotech PPMs can utilize a structured architectural framework to enhance decision-making processes
- Explore how analytics and data-driven approaches can increase the Probability of Technical Success (PTS) and provide informed options for timeline, scope, and budget scenarios
- Learn how integrating these methods into drug development plans leads to better project and portfolio outcomes.
11:15am Networking Break
11:45am Getting the Right Data: Ensuring Current, Reliable, & Complete Data for Informed Decision-Making in Pharma
Synopsis
- Implementing robust processes to guarantee that data inputs are current, reliable, and complete for informed decision making
- Strategies to overcome internal biases and ensure data accuracy, addressing
- Techniques for effectively communicating data insights to senior management, ensuring that the information is well-understood and actionable
12:15pm Standardizing Data Acquisition and Utilization Across Diverse Business Units
Synopsis
- Ensuring a seamless flow of information throughout the organization
- Implementing master data management practices to optimize data operations, governance, and stewardship for quicker, cleaner, and standardized data access
- Ensuring rapid, clean, and standardized data delivery to enable swift and effective decision-making, enhancing overall organizational efficiency
12:45pm Lunch & Networking
Optimizing the Approach to Strategic External Collaborations & Partnerships
1:45pm Fireside Chat: Biotech and Pharma Collaborations: Diverse Perspectives and Strategic Choices in Partnering
Synopsis
This insightful session will explore the diverse strategic intricacies that drive successful partnerships between biotech and pharma companies.
Key topics will include:
- Strategic Motivations and Benefits: Understanding the key drivers for both biotech and pharma in forming partnerships, from resource sharing and risk mitigation to market expansion and technological advancements
- What Each Looks for in a Partner: Analysing the specific attributes and qualities that biotech and pharma companies seek in potential partners, such as complementary expertise, cultural fit, financial stability, and strategic alignment
- Measuring Success and Value: Examining how each sector evaluates the success and value of partnerships, including milestones, performance metrics, and long-term strategic alignment
- Navigating Challenges and Building Trust: Addressing the common challenges faced in collaborations, such as aligning goals, managing expectations, and fostering trust and communication between partners
2:30 pm 2:30pm Innovative Collaborations: Exploring Non-Classical Partnerships Between Foundations and Pharma
Synopsis
- Diverse contributions that foundations bring to partnerships with pharmaceutical companies, including disease domain knowledge, research tools, funding support, stakeholder engagement, and advocacy for patient groups
- Examining various operational models used in non-classical partnerships employing various levels of engagement, such as research enablement, collaborative research, and contract-based funding to advance medical innovation
- Analyzing the impact of these partnerships on accelerating research and development efforts, enhancing innovation in drug discovery and biomarkers, and overcoming barriers in disease specific research
Navigating Biopharma’s Dynamic Challenges of Commercial Viability
3:00pm Roundtable Discussion: Determining Commercial Viability of Assets in Dynamic Market Conditions
Synopsis
Market changes underscore the complexity and dynamic nature of the pharmaceutical industry, requiring companies to adapt swiftly and strategically to maintain commercial viability and capitalize on emerging opportunities.
Discuss with peers the challenges, implications and opportunities associated with:
- Shifting economic factors like the Inflation Reduction Act
- Evolving healthcare reforms affecting Medicare Reimbursement Rates
- Competitive impact of new entrants, generics or biosimilars